Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus SULFOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus SULFOSE.
SULFACETAMIDE SODIUM vs SULFOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitively inhibits dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Sulfonamide antibiotic; inhibits bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth.
1-2 drops of 10-30% solution into the conjunctival sac every 2-3 hours initially, tapering as infection resolves. Ointment: 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
Meningococcal meningitis: 100 mg/kg/day intravenously in 4 divided doses (maximum 6 g/day). For other infections: 2-4 g/day IV/IM in 3-4 divided doses.
None Documented
None Documented
7-12.8 hours (prolonged in renal impairment; requires dosing adjustment in CrCl <50 mL/min).
Terminal elimination half-life: 3-4 hours in patients with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 85-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal: ~90% as unchanged drug via glomerular filtration; biliary/fecal: <10%.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic